Abstract

DIEUZEIDE, Guillermo; PUCHULU, Félix; SANABRIA, Hugo  and  SINAY, Isaac. Efectos cardiovasculares de los nuevos fármacos no insulínicos en diabetes. Medicina (B. Aires) [online]. 2018, vol.78, n.3, pp.185-193. ISSN 0025-7680.

Diabetes mellitus is currently a serious public health problem worldwide, that increases the risk of presenting microvascular and macrovascular complications. Although achieving the recommended blood glucose goals reduces the risk of microvascular complications, the effect of the drugs used to treat hyperglycemia on macrovascular complications and cardiovascular death is a cause for concern. In this context, the regulatory agencies have modified the regulations for the approval of new drugs in diabetes, by adding the need to demonstrate that they are capable of lowering blood glucose levels together with a solid assessment of cardiovascular safety. The objective of this study is to review the cardiovascular effects of the new families of non-insulin drugs, with special emphasis on their effect on the risk of major cardiovascular events. In recent years, it has finally been confirmed that some of the drugs used to treat diabetes are not only safe from a cardiovascular point of view, but have even shown capacity to reduce the risk of cardiovascular disease in type 2 diabetes mellitus. The evidence obtained determined the updating of some current therapeutic guidelines when cardiovascular risk should be considered a fundamental variable at the time of therapeutic choice in patients with diabetes.

Keywords : Diabetes mellitus; Glucagon-like peptide-1 receptor agonists (GLP-1 RA); Sodium-glucose transporter-2 (SGLT2) inhibitor; Cardiovascular safety; Major cardiovascular events (MACE).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )